Barnes & Noble Inc. (NYSE: BKS) surprised Wall Street today by reporting quarterly earnings that did not suck as bad analysts expected, mainly because it was able to control costs. The question is whether this is sustainable.
Net income at the world's largest bookseller fell to $15.4 million, or 27 cents a share, from $18.05 million, or 26 cents, a year earlier. Sales dropped 1.6% to $1.2 billion from a year earlier when J.K. Rowling's Harry Potter and the Deathly Hallows was flying off the shelves. Barnes & Noble store sales decreased 1.6% to $1.1 billion, with comparable store sales decreasing 4.7%. Barnes & Noble.com sales rose 3.6% to $99.8 million.
Excluding a one-time tax benefit, profit was 15 cents, five cents ahead of the 10-cent average estimate of analysts surveyed by Bloomberg. It was also higher than the company's guidance of 8 cents to 13 cents a share. Gross margins were stronger because of the greater utilization rates of its distribution centers and a lower markdown rate. Selling and administrative expenses fell in the quarter.
Of course, Barnes & Noble will continue to struggle as consumers cut back on their discretionary purchases. Moreover, Amazon.com Inc. (NASDAQ: AMZN) is not going anywhere soon. The company expects to lose 10 to 15 cents in the third quarter. It also lowered its full-year comparable same store sales guidance from "slightly negative to a decrease in the low single digits." The company is maintaining its full-year earnings guidance of $1.70 to $1.90.
At this rate, the company may be able to ride out the economic downturn until it can find a private equity buyer which is about the only hope for shareholders.
Last updated: February 12, 2012: 04:30 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
TheFlyOnTheWall.com Headlines
- Arab league to ask U.N. for a peacekeeping force in Syria, WSJ says
- Apple asks for preliminary injunction of Samsung Galaxy Nexus, AppleInsider says
- Some walnut growers want to stop selling to Diamond, Reuters says
- EASA orders Airbus A380s to be inspected, Der Spiegel says
- Sikorsky signs MOU with ASESA
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?

